Current Report Filing (8-k)
May 11 2023 - 4:17PM
Edgar (US Regulatory)
0001360214
false
0001360214
2023-05-11
2023-05-11
0001360214
HROW:CommonStock0.001ParValuePerShareMember
2023-05-11
2023-05-11
0001360214
HROW:Sec8.625SeniorNotesDue2026Member
2023-05-11
2023-05-11
0001360214
HROW:Sec11.875SeniorNotesDue2027Member
2023-05-11
2023-05-11
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 11, 2023
HARROW
HEALTH, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-35814 |
|
45-0567010 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
102
Woodmont Blvd., Suite 610 |
|
|
Nashville,
Tennessee |
|
37205 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (615) 733-4730
|
Not
Applicable |
|
|
(Former
Name or Former Address, if Changed Since Last Report) |
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
on exchange on which registered |
Common
Stock, $0.001 par value per share |
|
HROW |
|
The
Nasdaq Stock Market LLC |
8.625%
Senior Notes due 2026 |
|
HROWL |
|
The
Nasdaq Stock Market LLC |
11.875%
Senior Notes due 2027 |
|
HROWM |
|
The
Nasdaq Stock Market LLC |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2
of the Securities Act of 1934: Emerging growth company ☐
If
any emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
2.02 Results of Operations and Financial Condition.
On
May 11, 2023, Harrow Health, Inc. (the “Company”) issued a press release and a letter to stockholders announcing its financial
results for the period ended March 31, 2023 and an update on recent corporate events. The press release and letter to stockholders are
being furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K.
Item
7.01. Regulation FD Disclosure
Attached
as Exhibit 99.3 to this Item 7.01 is a presentation of the Company, that is being used by the management of the Company at investor conferences
and at meetings describing the Company.
The
information furnished under Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibits 99.1, 99.2 and 99.3, shall not
be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that Section. The information in Items 2.02 and 7.01, including Exhibits 99.1,
99.2 and 99.3, shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange
Act, except to the extent it is specifically incorporated by reference but regardless of any general incorporation language in such filing.
The
information furnished under Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibits 99.1, 99.2 and 99.3, shall not
be deemed to constitute an admission that such information or exhibit is required to be furnished pursuant to Regulation FD or that such
information or exhibit contains material information that is not otherwise publicly available. In addition, the Company does not assume
any obligation to update such information or exhibit in the future.
Item
9.01. Financial Statements and Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| HARROW
HEALTH, INC. |
|
|
|
Dated:
May 11, 2023 |
By: |
/s/
Andrew R. Boll |
|
Name: |
Andrew
R. Boll |
|
Title: |
Chief
Financial Officer |
Harrow (NASDAQ:HROW)
Historical Stock Chart
From Mar 2024 to Apr 2024
Harrow (NASDAQ:HROW)
Historical Stock Chart
From Apr 2023 to Apr 2024